Immutep, GWU Cancer Center Launch Neoadjuvant Efti Study
Immutep has initiated an investigator-initiated Phase II trial of eftilagimod alfa (efti) as a neoadjuvant therapy in early-stage HR+/HER2-negative...
Jon Napitupulu
Intellia’s Promising Longer-Term Nex-Z Data for ATTR Emerge
Intellia Therapeutics will present longer-term data from its ongoing Phase 1 trial of Nexiguran ziclumeran (Nex-Z), an investigational in...
Starpharma Announces Collaboration, License Deal with Genentech
Starpharma has signed a collaboration and license agreement with Genentech to apply its DEP dendrimer drug-delivery platform to Genentech...
Plus Therapeutics Gets Additional $1.9M Advance From CPRIT
Plus Therapeutics has received an additional $1.9 million advance from the Cancer Prevention and Research Institute of Texas, part...
Helio: A European CDMO Dedicated to In Vitro Diagnostics
Helio Diagnostics has launched as a Europe-based, end-to-end contract development and manufacturing partner focused exclusively on in vitro diagnostics....
Idorsia’s Quviviq Launches in China, Expands Globally
Simcere has launched Quviviq (daridorexant) in mainland China for adult insomnia, with a notable regulatory distinction: the drug enters...
NexoBrid Takes Spotlight at European Burns Association Congress
MediWound’s NexoBrid will take center stage at the European Burns Association Congress in Berlin this week, featured across 36...
Clearmind Medicine Secures $10M for Strategic Opportunities
Clearmind Medicine has arranged up to $10 million in convertible note financing with institutional investors, securing an initial $500,000...
NTA Implant Solidifies Leadership with MDR Certification
NTA Implant, the dental implant brand of Switzerland-based Pilatus Swiss Dental GmbH, has secured European Union Medical Device Regulation...
Bylvay (odévixibat) Approved in Japan for Rare Liver Disease
Japan’s Ministry of Health, Labour and Welfare has approved Bylvay (odevixibat) for pruritus associated with progressive familial intrahepatic cholestasis...